A new approach against non-small-cell lung cancer (NSCLC) has combined immunotherapy with molecularly targeted therapy to activate the immune response and inhibit oncogenic pathways, which prevented tumor progression and eliminated cancer cells. Brigham and Women’s Hospital scientists have developed nanoparticles loaded with antibody conjugates that could deliver large amounts of treatment to the tumor tissue. This new strategy could improve the results of conventional immunotherapy in these patients and reduce toxicity of existing treatments.
During the basic science morning track on the last day of this year’s Annual Congress of the European Hematology Association (EHA), the attention was focused on oncogenic transcription factors and complexes considered turning points within the acute myeloid leukemia (AML) arena.
Atomwise Inc. reported the development and preclinical evaluation data of ATMW-DC, a novel orally available allosteric inhibitor of TYK2 developed using Atomwise’s drug discovery platform Atomnet, for the potential treatment of psoriatic inflammation.
Odyssey Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of autoimmune diseases, chronic granulomatous disease, neurodegeneration, inflammatory disorders and cancer.
Graviton Bioscience BV has divulged new Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of arteriosclerosis, cancer, idiopathic pulmonary fibrosis, metabolic syndrome, multiple sclerosis, psoriasis, scleroderma and uveitis, among others.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed translation initiation factor 2B (eIF2B) activators reported to be useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, and autoimmune, eye, renal and dermatological disorders, among others.
The search for an effective therapy for liver fibrosis continues. A recent study by researchers at Medical University of South Carolina and collaborators explored the potential of a new compound, LP-340, as a treatment for liver fibrosis.
Cellular communication network factor 1 (CCN1) is overexpressed in endothelial cells and synovial tissues of patients with rheumatoid arthritis. The effects of inhibiting CCN1 in two experimental models of RA were tested.
RSS
